UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit

BMJ open, 2022-11, Vol.12 (11), p.e050590

2022

Volltextzugriff (PDF)

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

Journal of clinical pathology, 2009-04, Vol.62 (4), p.373-376

2009

Volltextzugriff (PDF)

Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development

Journal of clinical pathology, 2008-08, Vol.61 (8), p.891-896

2008

Volltextzugriff (PDF)

POS0686 BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Annals of the rheumatic diseases, 2021-06, Vol.80 (Suppl 1), p.588-589

2021

Volltextzugriff (PDF)

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Lupus science & medicine, 2020-10, Vol.7 (1), p.e000424

2020

Volltextzugriff (PDF)

Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD

Annals of the rheumatic diseases, 2016-06, Vol.75 (6), p.958-964

2016

Volltextzugriff (PDF)

3 Investigating the utility of subcutaneous implantable cardioverter-defibrillators in the adult congenital heart disease population

Heart (British Cardiac Society), 2018-02, Vol.104 (Suppl 2), p.A1

2018

Volltextzugriff (PDF)

Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation

Heart (British Cardiac Society), 2020-12, Vol.106 (24), p.1919-1926

2020

Volltextzugriff (PDF)

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies

Journal for immunotherapy of cancer, 2021-07, Vol.9 (7), p.e002673

2021

Volltextzugriff (PDF)

Multicentre, cross-cultural, population-based, case–control study of physical activity as risk factor for amyotrophic lateral sclerosis

Journal of neurology, neurosurgery and psychiatry, 2018-08, Vol.89 (8), p.797-803

2018

Volltextzugriff (PDF)

THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.416

2016

Volltextzugriff (PDF)

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.412

2016

Volltextzugriff (PDF)

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002179

2021

Volltextzugriff (PDF)

1 Congenitally corrected transposition of the great arteries: indications for CRT?

Heart (British Cardiac Society), 2017-04, Vol.103 (Suppl 3), p.A1

2017

Volltextzugriff (PDF)

OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL

Annals of the rheumatic diseases, 2020-06, Vol.79 (Suppl 1), p.29-30

2020

Volltextzugriff (PDF)

THU0198 Baricitinib Effects on Lipid and NMR-Measured Lipoprotein Profiles in A Phase 3 Study in Patients with Rheumatoid Arthritis

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.257-258

2016

Volltextzugriff (PDF)

LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

Annals of the rheumatic diseases, 2015-06, Vol.74 (Suppl 2), p.79-79

2015

Volltextzugriff (PDF)

2 Suitability of univentricular patients for cardiac resynchronisation therapy

Heart (British Cardiac Society), 2017-04, Vol.103 (Suppl 3), p.A1

2017

Volltextzugriff (PDF)

20 Do atriopulmonary (AP) fontan dimensions using CMR influence the development of atrial tachyarrhythmia?

Heart (British Cardiac Society), 2016-05, Vol.102 (Suppl 3), p.A14-A15

2016

Volltextzugriff (PDF)

Multiple sclerosis in Malta in 1999: an update

Journal of neurology, neurosurgery and psychiatry, 2002-09, Vol.73 (3), p.256-260

2002

Volltextzugriff (PDF)

A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies

Annals of the rheumatic diseases, 2016-02, Vol.75 (Suppl 1), p.A62-A62

2016

Volltextzugriff (PDF)

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1

Annals of the rheumatic diseases, 2016-06, Vol.75 (Suppl 2), p.412-413

2016

Volltextzugriff (PDF)

1 – 25 von 64

Suche als RSS-Feed

Aktive Filter

KollektionBritish Medical Journals Online Archive (BMJ)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(62)
Mit Volltextzugriff
(42)

Publikationsform

Artikel
(63)
Berichte
(1)

Sprache

Englisch
(64)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Journals@Ovid Full Text
(56)
EZB Electronic Journals Library
(51)
BMJ Journals Archiv - DFG Nationallizenzen
(40)
MEDLINE
(31)
JSTOR All Journals
(14)
Single Journals
(8)
Applied Social Sciences Index & Abstracts (ASSIA)
(3)
Springer Online Journals
(3)

3 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

What is the impact of targeted therapies given within phase I trials on the cognitive function of patients with advanced cancer: a mixed-methods exploratory study conducted in an early clinical trials unit

Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity

Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development

POS0686 BARICITINIB DECREASES ANTI-DSDNA AND IGG ANTIBODIES IN ADULTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS FROM A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways

Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD

3 Investigating the utility of subcutaneous implantable cardioverter-defibrillators in the adult congenital heart disease population

Changes in quality of life, cognition and functional status following catheter ablation of atrial fibrillation

Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies

Multicentre, cross-cultural, population-based, case–control study of physical activity as risk factor for amyotrophic lateral sclerosis

THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib

Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance

Enhancing quality and impact of early phase dose-finding clinical trial protocols: SPIRIT Dose-finding Extension (SPIRIT-DEFINE) guidance

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy

PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

1 Congenitally corrected transposition of the great arteries: indications for CRT?

Prevalence of asthma-like symptoms with ageing

OP0045 DELINEATION OF A PROINFLAMMATORY CYTOKINE PROFILE TARGETED BY JAK1/2 INHIBITION USING BARICITINIB IN A PHASE 2 SLE TRIAL

THU0198 Baricitinib Effects on Lipid and NMR-Measured Lipoprotein Profiles in A Phase 3 Study in Patients with Rheumatoid Arthritis

LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study

2 Suitability of univentricular patients for cardiac resynchronisation therapy

20 Do atriopulmonary (AP) fontan dimensions using CMR influence the development of atrial tachyarrhythmia?

Multiple sclerosis in Malta in 1999: an update

A7.16 Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies

THU0609 Patient-Reported Outcomes from A Phase 3 Study of Baricitinib versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis and An Inadequate Response To Background Methotrexate Therapy: Table 1

Aktive Filter

Suchergebnisse filtern